Bronstein, Gewirtz & Grossman, LLC Is Investigating Stryker Corporation (SYK) And Encourages Investors to Connect

By ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / September 17, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Stryker Corporation ("Stryker" or "the Company") (NYSE:SYK). Investors who purchased Stryker securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/stryker-corporation-syk-class_action_lawsuit.

Stryker Investigation Details

On July 30, 2026, Stryker reported its second-quarter 2026 results. Among other things, the Company reported that a "supply disruption resulted in a meaningful backorder situation with lost sales in the quarter. We have addressed the issue, and back orders should reach a manageable level by the end of Q3." Following this news, Stryker's stock price dropped $22.34 or 6.43% to close at $325.70 per share on July 31, 2026. Then on September 8, 2026, the Company participated in the Wells Fargo Healthcare Conference, during which the Company's CFO Preston Wells told investors the Company had "anticipated that" the manufacturing issue "would rectify itself in the third quarter." But "[w]hat we're seeing is that is continuing into the third quarter and certainly, it will continue." Following this news, Stryker's stock price dropped $26.70 per share, or 8.8%, to close at $276.43 per share on September 8, 2026.

What's Next for Stryker Investors?

If you are aware of any facts relating to this investigation or purchased Stryker securities, you can assist this investigation by visiting the firm's site: bgandg.com/cases/stryker-corporation-syk-class_action_lawsuit. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Stryker Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Stryker Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View the original press release on ACCESS Newswire

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.